×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: Merck Drug Trial

Merck Stops Trial for Potential Blood Thinner

Thursday, 13 January 2011 12:06 PM EST

Shares of Merck & Co. are falling after the drugmaker says it has halted one late-stage trial of a potential blood thinner and will immediately stop giving the drug in another study to patients who have had a stroke.

The Whitehouse Station, N.J., company is studying vorapaxar for the prevention of cardiac events. Patients with acute coronary syndrome will stop taking it in one study because it reached a pre-determined number of medical issues like cardiovascular deaths, heart attacks or strokes.

A second study will continue with about 75 percent of its patients, minus those who had a stroke either before or during the trial.

The company's shares are down $2.03, or 5.5 percent, to $35.12 in morning trading.

© Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Companies
Shares of Merck Co. are falling after the drugmaker says it has halted one late-stage trial of a potential blood thinner and will immediately stop giving the drug in another study to patients who have had a stroke.The Whitehouse Station, N.J., company is studying...
Merck Drug Trial
119
2011-06-13
Thursday, 13 January 2011 12:06 PM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Get Newsmax Text Alerts
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved